title: Sildenafil and assessment of pulmonary arterial reactivity in heart failure.
abstract: Pulmonary hypertension is a daunting accompaniment of advanced heart failure. Efforts to safely and consistently lower pulmonary vascular resistance are necessary but fraught with challenges. In this report the authors explore the novel use of sildenafil, an inhibitor of phosphodiesterase-5, in tackling pulmonary hypertension in heart failure. The salutary effects of this agent deserve further study.
authors.affiliation: Cardiomyopathy and Heart Transplantation Center, Ochsner Clinic Foundation, New Orleans, LA 70121, USA.
authors.forename: Jamshid
authors.initials: J
authors.lastname: Alaeddini
authors.forename: Patricia
authors.initials: P
authors.lastname: Uber
authors.forename: Myung H
authors.initials: MH
authors.lastname: Park
authors.forename: Robert L
authors.initials: RL
authors.lastname: Scott
authors.forename: Mandeep R
authors.initials: MR
authors.lastname: Mehra
mesh_terms: D015106:3',5'-Cyclic-GMP Phosphodiesterases / Q000627:therapeutic use*; D006333:Heart Failure / Q000150:complications; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011687:Purines; D000068677:Sildenafil Citrate; D013450:Sulfones
chemical_list: D010879:Piperazines; D011687:Purines; D013450:Sulfones; D000068677:Sildenafil Citrate; D015106:3',5'-Cyclic-GMP Phosphodiesterases